Cover Image
市場調查報告書

發炎性腸道疾病的全球市場:2015年∼2019年

Global Inflammatory Bowel Disease Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 328832
出版日期 內容資訊 英文 146 Pages
訂單完成後即時交付
價格
Back to Top
發炎性腸道疾病的全球市場:2015年∼2019年 Global Inflammatory Bowel Disease Market 2015-2019
出版日期: 2015年04月15日 內容資訊: 英文 146 Pages
簡介

全球發炎性腸道疾病的市場預計從2014年到2019年以3.95%的年複合成長率成長。

本報告提供發炎性腸道疾病的治療藥的市場相關調查、發炎性腸道疾病概要、各原因、原因、盛行率、診斷法、治療方法、產品研發線、地區、疾病區分、藥物類別、分子類型、劑型、投藥途徑的市場分析、市場規模的變化與預測、市場成長的各種影響因素分析、競爭環境,以及主要企業的簡介等彙整。

第1章 摘要整理

第2章 簡稱一覽

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

第5章 簡介

第6章 疾病概要

  • 疾病的理解
  • 病因
    • 自體免疫反應
    • 遺傳基因
    • 環境
  • 克隆氏症的階段
  • 流行病學
    • 全球盛行率
    • 美國
    • 英國
  • 症狀
    • 腹瀉
    • 熱、倦怠感
    • 腹痛、痙攣
    • 肛門周圍疾病、血便
    • 食慾衰退、體重減少
  • 診斷、檢驗
    • 初期檢驗
    • 內視鏡、切片檢查
    • 染色內視鏡
    • 小腸成像
  • 治療
    • 投藥
    • 飲食習慣、營養
    • 手術

第7章 疾病概要:潰瘍性大腸炎

  • 疾病的理解
  • 病因
    • 自體免疫反應
    • 遺傳
    • 環境因素
  • 預後
  • 流行病學
    • 全球
    • 英國
    • 美國
  • 症狀
  • 診斷、檢驗
  • 治療
    • 藥物治療
    • 外科手術

第8章 產品研發線

  • 克隆氏症的開發平台狀況
    • 新的治療選擇
  • 潰瘍性大腸炎的開發平台狀況

第9章 市場環境

  • 全球市場
  • 市場規模、預測
  • 美國市場
    • 市場規模、預測
  • 歐盟市場
    • 市場規模、預測
  • 日本市場
    • 市場規模、預測
  • 波特的五力分析

第10章 各疾病種類市場

  • 克隆氏症
  • 潰瘍性大腸炎

第11章 全球克隆氏症市場

  • 市場規模、預測
  • 美國市場
    • 市場規模、預測
  • 日本市場
    • 市場規模、預測

第12章 全球潰瘍性大腸炎市場

  • 市場規模、預測

第13章 各類藥物市場

第14章 各分子類型市場

  • 生物製藥
  • 小分子

第15章 各劑型市場

  • 固態
  • 液體

第16章 各投藥途徑市場

  • 口服
  • 非口服

第17章 各地區市場

  • 全球發炎性疾病市場:各地區
  • 全球克隆氏症、潰瘍性大腸炎市場:各地區
  • 全球克隆氏症市場:各地區
  • 全球潰瘍性大腸炎市場:各地區

第18章 主要國家市場

  • 目前主要國家
  • 主要國家的未來
  • 美國
  • 日本

第19章 購買標準

第20章 市場成長推動要素

第21章 推動要素與其影響

第22章 市場課題

第23章 推動要素及課題的影響

第24章 市場趨勢

第25章 趨勢與其影響

第26章 供應商環境

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • 主要藥物的競爭評估
    • AbbVie
    • Janssen Pharmaceuticals
    • Merck
    • Biogen Idec
    • UCB
    • Shire
  • 其他卓越供應商

第27章 主要供應商分析

  • AbbVie
  • Biogen Idec
  • Janssen Pharmaceuticals
  • Merck
  • Shire
  • UCB
    • 主要資料
    • 產業概要
    • 各部門收益
    • 各地區收益
    • 產業策略
    • 近幾年的發展趨勢
    • SWOT分析等

第28章 相關報告

圖表

目錄
Product Code: IRTNTR5692

About Inflammatory Bowel Disease

Inflammatory bowel disease is a condition includes a group of autoimmune diseases such as Crohn's disease and ulcerative colitis. It causes chronic inflammation of a specific part or the entire GI tract. Both Crohn's disease and ulcerative colitis include symptoms such as severe persistent diarrhea, abdominal cramps and pain, rectal bleeding, fatigue, and weight loss. Inflammatory bowel disease can also prove to be life-threatening for the patients. Ulcerative colitis generally affects the colon, where inflammation and ulcers develop in the innermost lining of the colon and the rectum of a patient. Crohn's disease causes inflammation of the lining of the GI tract. The inflammation in Crohn's disease affects various areas of the GI tract such as the large intestine and small intestine, or both. Inflammatory bowel disease is a chronic medical condition, which has no permanent cure and demands a lifetime of treatment and management. The preferred treatment options include anti-inflammatory steroidal products and immuno-suppressive agents such as the TNF-α inhibitors.

TechNavio's analysts forecast the Global Inflammatory Bowel Disease market to grow at a CAGR of 3.95 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Inflammatory Bowel Disease market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of inflammatory bowel disease. The market includes data from the sales of various drusg which are used for the treatment of Crohn's Disease and Ulcerative Colitis.

On the basis of the functioning of the drugs used for treatment, the Global Inflammatory Bowel Disease market is categorized into three segments.

  • 5-ASA
  • Antibiotics
  • Immunomodulators

On the basis of the type of molecule used for treatment, the Global Inflammatory Bowel Disease market is categorized into two segments.

  • Biologics
  • Small Molecules

On the basis of route of administration adopted for the treatment, the Global Inflammatory Bowel Disease market is categorized into two segments.

  • Oral
  • Parenteral

On the basis of the form of drug used to treat the disease, the Global Inflammatory Bowel Disease market is categorized into two segments.

  • Solid
  • Liquid

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Inflammatory Bowel Disease market. The vendor landscape includes an analysis of the major vendors, along with the competitive performances of their portfolios. In addition, the report discusses the major drivers, challenges and trends influencing the market. In addition, late-stage pipeline molecules developed for the treatment of inflammatory bowel disease are discussed.

TechNavio's report, Global Inflammatory Bowel Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the landscape of the Global Inflammatory Bowel Disease market and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Abbvie
  • Biogen Idec
  • Janssen Pharmaceuticals
  • Merck & Company
  • Shire
  • UCB

Other Prominent Vendors

  • Amgen
  • Akebia Therapeutics
  • Boehringer Ingelheim
  • Celltrion
  • ChemoCentryx
  • Ferring Pharmaceuticals
  • Galapagos
  • Genentech
  • Merck
  • Mitsubishi Tanabe
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Salix Pharmaceuticals

Market Driver

  • Increase in Instances of Inflammatory Bowel Disease
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Drugs
  • For a full, detailed list, view our report

Market Trend

  • Dominance of Market by Biologics
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market overview
  • 03.2. Product offerings

04. Market Research Methodology

  • 04.1. Market research process
  • 04.2. Research methodology

05. Introduction

06. Disease Overview: Crohn's Disease

  • 06.1. Understanding the disease
  • 06.2. Etiology
    • 06.2.1. Autoimmune reaction
    • 06.2.2. Genes
    • 06.2.3. Environment
  • 06.3. Stages of Crohn's disease
  • 06.4. Epidemiology
    • 06.4.1. Worldwide prevalence of Crohn's disease
    • 06.4.2. US
    • 06.4.3. UK
  • 06.5. Symptoms
    • 06.5.1. Diarrhea
    • 06.5.2. Fever and fatigue
    • 06.5.3. Abdominal pain and cramping
    • 06.5.4. Perianal disease and blood in stool
    • 06.5.5. Reduced appetite and weight loss
  • 06.6. Diagnosis and testing
    • 06.6.1. Early tests and exams
    • 06.6.2. Endoscopy and biopsy
    • 06.6.3. Chromoendoscopy
    • 06.6.4. Small intestinal imaging
  • 06.7. Treatment
    • 06.7.1. Medication
    • 06.7.2. Diet and nutrition
    • 06.7.3. Surgery

07. Disease Overview: Ulcerative Colitis

  • 07.1. Understanding the disease
  • 07.2. Etiology
    • 07.2.1. Autoimmune reaction
    • 07.2.2. Genetics
    • 07.2.3. Environmental factors
  • 07.3. Prognosis
  • 07.4. Epidemiology
    • 07.4.1. Global
    • 07.4.2. UK
    • 07.4.3. US
  • 07.5. Symptoms
  • 07.6. Diagnosis and testing
  • 07.7. Treatment
    • 07.7.1. Medical treatment options
    • 07.7.2. Surgical procedures

08. Pipeline Portfolio

  • 08.1. Crohn's disease pipeline landscape
    • 08.1.1. Some emerging therapeutic options
  • 08.2. Ulcerative colitis pipeline landscape

09. Market Landscape

  • 09.1. Global inflammatory bowel disease market
  • 09.2. Market size and forecast
  • 09.3. Inflammatory bowel disease market in US
    • 09.3.1. Market size and forecast
  • 09.4. Inflammatory bowel disease market in EU
    • 09.4.1. Market size and forecast
  • 09.5. Inflammatory bowel disease market in Japan
    • 09.5.1. Market size and forecast
  • 09.6. Five forces analysis

10. Market Segmentation by Type of Disease

  • 10.1. Crohn's disease
  • 10.2. Ulcerative colitis

11. Global Crohn's Disease Market

  • 11.1. Market size and forecast
  • 11.2. Crohn's disease market in US
    • 11.2.1. Market size and forecast
  • 11.3. Crohn's disease market in Japan
    • 11.3.1. Market size and forecast

12. Global Ulcerative Colitis Market

  • 12.1. Market size and forecast

13. Market Segmentation by Drug Class

14. Market Segmentation by Type of Molecule

  • 14.1. Biologics
  • 14.2. Small molecules

15. Market Segmentation by Dosage Form

  • 15.1. Solid
  • 15.2. Liquid

16. Market Segmentation by Route of Administration

  • 16.1. Oral
  • 16.2. Parenteral

17. Geographical Segmentation

  • 17.1. Segmentation of global inflammatory market by geography
  • 17.2. Segmentation of global Crohn's disease and ulcerative colitis markets by geography
  • 17.3. Segmentation of global Crohn's disease market by geography
  • 17.4. Segmentation of global ulcerative colitis market by geography

18. Key Leading Countries

  • 18.1. Key leading countries 2014
  • 18.2. Key leading countries 2019
  • 18.3. US
  • 18.4. Japan

19. Buying Criteria

20. Market Growth Drivers

21. Drivers and their Impact

22. Market Challenges

23. Impact of Drivers and Challenges

24. Market Trends

25. Trends and their Impact

26. Vendor Landscape

  • 26.1. Competitive scenario
    • 26.1.1. Key news
    • 26.1.2. Mergers and acquisitions
  • 26.2. Market share analysis 2014
    • 26.2.1. Competitive assessment of top drugs for inflammatory bowel disease
    • 26.2.2. AbbVie
    • 26.2.3. Janssen Pharmaceuticals
    • 26.2.4. Merck
    • 26.2.5. Biogen Idec
    • 26.2.6. UCB
    • 26.2.7. Shire
  • 26.3. Other and future prominent vendors

27. Key Vendor Analysis

  • 27.1. AbbVie
    • 27.1.1. Key facts
    • 27.1.2. Business overview
    • 27.1.3. Product segmentation by revenue 2013
    • 27.1.4. Product segmentation by revenue 2012 and 2013
    • 27.1.5. Sales by geography
    • 27.1.6. Business strategy
    • 27.1.7. Key developments
    • 27.1.8. SWOT analysis
  • 27.2. Biogen Idec
    • 27.2.1. Key facts
    • 27.2.2. Business overview
    • 27.2.3. Business segmentation by revenue 2013
    • 27.2.4. Geographical segmentation by revenue 2013
    • 27.2.5. Business strategy
    • 27.2.6. Key developments
    • 27.2.7. SWOT analysis
  • 27.3. Janssen Pharmaceuticals
    • 27.3.1. Key facts
    • 27.3.2. Business overview
    • 27.3.3. Recent developments
    • 27.3.4. SWOT analysis
  • 27.4. Merck
    • 27.4.1. Key facts
    • 27.4.2. Business overview
    • 27.4.3. Business segmentation by revenue 2013
    • 27.4.4. Business segmentation by revenue 2012 and 2013
    • 27.4.5. Sales by geography
    • 27.4.6. Business strategy
    • 27.4.7. Key developments
    • 27.4.8. SWOT analysis
  • 27.5. Shire
    • 27.5.1. Key facts
    • 27.5.2. Business overview
    • 27.5.3. Geographical segmentation by revenue 2013
    • 27.5.4. Business strategy
    • 27.5.5. Recent developments
    • 27.5.6. SWOT analysis
  • 27.6. UCB
    • 27.6.1. Key facts
    • 27.6.2. Business overview
    • 27.6.3. Product segmentation by revenue 2013
    • 27.6.4. Product segmentation by revenue 2012 and 2013
    • 27.6.5. Geographical segmentation by revenue 2013
    • 27.6.6. Business strategy
    • 27.6.7. Recent developments
    • 27.6.8. SWOT analysis

28. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market research methodology
  • Exhibit 2: Challenges and drivers of global inflammatory bowel disease market
  • Exhibit 3: Overview of Crohn's disease
  • Exhibit 4: Classification of Crohn's disease
  • Exhibit 5: Expected number of global Crohn's disease cases 2015-2022
  • Exhibit 6: Global variation in incidence rates for Crohn's disease in 2012 (in %)
  • Exhibit 7: Prevalence of Crohn's disease in US
  • Exhibit 8: Incidence of Crohn's disease in US
  • Exhibit 9: Symptoms of Crohn's disease
  • Exhibit 10: Crohn's disease: diagnosis and testing
  • Exhibit 11: Crohn's disease: treatment
  • Exhibit 12: Treatment landscape for Crohn's disease
  • Exhibit 13: Crohn's disease: treatment pathway
  • Exhibit 14: Ulcerative colitis: Symptoms
  • Exhibit 15: Diagnostic approach for ulcerative colitis
  • Exhibit 16: Treatment options for ulcerative colitis
  • Exhibit 17: Surgical procedures to treat ulcerative colitis
  • Exhibit 18: Crohn's disease: pipeline portfolio
  • Exhibit 19: Crohn's disease clinical trial by phase
  • Exhibit 20: Crohn's disease clinical trial by status
  • Exhibit 21: Ulcerative colitis: pipeline portfolio
  • Exhibit 22: Snapshot of global inflammatory bowel disease market 2014
  • Exhibit 23: Global inflammatory bowel disease market 2014-2019 ($ million)
  • Exhibit 24: Inflammatory bowel disease market in US 2014-2019 ($ million)
  • Exhibit 25: Inflammatory bowel disease market in EU 2014-2019 ($ million)
  • Exhibit 26: Inflammatory bowel disease market in Japan 2014-2019 ($ million)
  • Exhibit 27: Segmentation of global inflammatory bowel disease market by type of disease
  • Exhibit 28: Segmentation of global inflammatory bowel disease market by type of disease 2014
  • Exhibit 29: Segmentation of global inflammatory bowel disease market by type of disease 2019
  • Exhibit 30: Revenue of global inflammatory bowel disease market 2014-2019 ($ million)
  • Exhibit 31: Snapshot of global Crohn's disease market 2014
  • Exhibit 32: Global Crohn's disease market 2014-2019 ($ million)
  • Exhibit 33: Crohn's disease market in US 2014-2019 ($ million)
  • Exhibit 34: Crohn's disease market in Japan 2014-2019 ($ million)
  • Exhibit 35: Snapshot of global ulcerative colitis market
  • Exhibit 36: Global ulcerative colitis market 2014-2019 ($ million)
  • Exhibit 37: Segmentation of global inflammatory bowel disease market by drug class
  • Exhibit 38: Benefits and risks of 5-ASA
  • Exhibit 39: Segmentation of global inflammatory bowel disease market by drug class 2014
  • Exhibit 40: Segmentation of global inflammatory bowel disease market by type of molecule
  • Exhibit 41: Segmentation of global inflammatory bowel disease market by type of molecule 2014
  • Exhibit 42: Segmentation of global inflammatory bowel disease market by dosage form
  • Exhibit 43: Segmentation of global inflammatory bowel disease market by dosage form 2014
  • Exhibit 44: Segmentation of global inflammatory bowel disease market by route of administration
  • Exhibit 45: Segmentation of global inflammatory bowel disease market by route of administration 2014
  • Exhibit 46: Segmentation of global inflammatory bowel disease market by geography 2014
  • Exhibit 47: Segmentation of global inflammatory bowel disease market by geography 2019
  • Exhibit 48: Segmentation of global Crohn's disease market by geography 2014
  • Exhibit 49: Segmentation of global ulcerative colitis market by geography 2014
  • Exhibit 50: Major drivers of global inflammatory bowel disease market
  • Exhibit 51: Major challenges in global inflammatory bowel disease market
  • Exhibit 52: Major trends in global inflammatory bowel disease market
  • Exhibit 53: Ranking of vendors 2014
  • Exhibit 54: YoY revenue of top drugs for inflammatory bowel disease 2010-2014 ($ million)
  • Exhibit 55: Revenue share of top drugs for inflammatory bowel disease 2010-2014
  • Exhibit 56: AbbVie: product portfolio
  • Exhibit 57: YoY global revenue of Humira 2009-2014 ($ million)
  • Exhibit 58: YoY revenue of Humira in US 2009-2014 ($ million)
  • Exhibit 59: YoY international revenue of Humira (except US) 2009-2014 ($ million)
  • Exhibit 60: Revenue comparison of Humira 2009-2014 ($ million)
  • Exhibit 61: Janssen: product portfolio
  • Exhibit 62: YoY global revenue of Remicade 2009-2014 ($ million)
  • Exhibit 63: YoY global revenue of Simponi 2010-2014 ($ million)
  • Exhibit 64: Merck: product portfolio
  • Exhibit 65: YoY global revenue of Remicade 2009-2014 ($ million)
  • Exhibit 66: YoY global revenue of Simponi 2010-2014 ($ million)
  • Exhibit 67: Biogen Idec: product portfolio
  • Exhibit 68: YoY global revenue of Tysabri 2009-2014 ($ million)
  • Exhibit 69: YoY revenue of Tysabri in US 2009-2014 ($ million)
  • Exhibit 70: YoY revenue of Tysabri in ROW 2009-2014 ($ million)
  • Exhibit 71: Global revenue of Tysabri 2009-2014 ($ million)
  • Exhibit 72: UCB: product portfolio
  • Exhibit 73: YoY global revenue of Cimzia 2010-2014 ($ million)
  • Exhibit 74: Shire: product portfolio
  • Exhibit 75: YoY global revenue of Lialda 2010-2014 ($ million)
  • Exhibit 76: AbbVie: product segmentation by revenue 2013
  • Exhibit 77: AbbVie: product segmentation by revenue 2012 and 2013 ($ million)
  • Exhibit 78: AbbVie: sales by geography 2013
  • Exhibit 79: Biogen Idec: business segmentation by revenue 2013
  • Exhibit 80: Biogen Idec: geographical segmentation by revenue 2013
  • Exhibit 81: Merck: business segmentation by revenue 2013
  • Exhibit 82: Merck: business segmentation by revenue 2012 and 2013 ($ billion)
  • Exhibit 83: Merck: sales by geography 2013
  • Exhibit 84: Shire: geographical segmentation by revenue 2013
  • Exhibit 85: UCB: product segmentation by revenue 2013
  • Exhibit 86: UCB: product segmentation by revenue 2012 and 2013 ($ million)
  • Exhibit 87: UCB: geographical segmentation by revenue 2013
Back to Top